Faith E Davies
University of Arkansas for Medical Science-Myeloma Institute
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Faith E Davies as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 08:32 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT03000634 · 2015-09: a Phase II Randomized, Open-label Study of Anti-signaling Lymphocytic Activation Molecule Monoclonal Antibody During Maintenance TherapyUniversity of Arkansas · withdrawn · Multiple Myeloma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 08:32 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 1 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 08:32 UTC. The ranking covers the 200 most relevant of 52 PubMed records, and a shared surname and initials can bring in a namesake. All 52 on PubMed
- 1,468 citationsRCR 31.7
- 736 citationsRCR 15.1
- Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma.J Clin Oncol · 2015472 citationsRCR 12.9
- 440 citationsRCR 11.1
- Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX Study.J Clin Oncol · 2013339 citationsRCR 9.4
- Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial.Lancet Oncol · 2019309 citationsRCR 11.7
- A compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic value.Blood · 2010307 citationsRCR 6.3
- The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis.Blood · 2012273 citationsRCR 7.9
- Aberrant global methylation patterns affect the molecular pathogenesis and prognosis of multiple myeloma.Blood · 2011213 citationsRCR 4.7
- 155 citationsRCR 3.9